Current therapies and new developments in NASH

Jean Francois Dufour; Quentin M. Anstee; Elisabetta Bugianesi; Stephen Harrison; Rohit Loomba; Valerie Paradis; Herbert Tilg; Vincent Wai Sun Wong; Shira Zelber-Sagi

doi:10.1136/gutjnl-2021-326874

Current therapies and new developments in NASH

Jean Francois Dufour, Quentin M. Anstee, Elisabetta Bugianesi, Stephen Harrison, Rohit Loomba, Valerie Paradis, Herbert Tilg, Vincent Wai Sun Wong, Shira Zelber-Sagi

School of Public Health

Research output: Contribution to journal › Review article › peer-review

Abstract

Non-alcoholic steatohepatitis is becoming the most importance etiology for advanced liver disease. The field made important progresses in the last years. The complexity of the pathophysiology of NASH is better understood. Multiple non-invasive criculating and imaging biomarkers have been tested. The importance of lifestyles has been reconised and several drugs are tested in clinical trials. This review adresses the challenges that face health care professionals in the management of NASH patients.

Original language	English
Article number	326874
Pages (from-to)	2123-34
Number of pages	12
Journal	Gut
Volume	71
Issue number	10
Early online date	16 Jun 2022
DOIs	https://doi.org/10.1136/gutjnl-2021-326874
State	E-pub ahead of print - 16 Jun 2022

Bibliographical note

Publisher Copyright:
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1136/gutjnl-2021-326874

Cite this

@article{872ffedd06be4c09a2c6ed7c9c63b726,

title = "Current therapies and new developments in NASH",

abstract = "Non-alcoholic steatohepatitis is becoming the most importance etiology for advanced liver disease. The field made important progresses in the last years. The complexity of the pathophysiology of NASH is better understood. Multiple non-invasive criculating and imaging biomarkers have been tested. The importance of lifestyles has been reconised and several drugs are tested in clinical trials. This review adresses the challenges that face health care professionals in the management of NASH patients.",

author = "Dufour, {Jean Francois} and Anstee, {Quentin M.} and Elisabetta Bugianesi and Stephen Harrison and Rohit Loomba and Valerie Paradis and Herbert Tilg and Wong, {Vincent Wai Sun} and Shira Zelber-Sagi",

note = "Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2022",

month = jun,

day = "16",

doi = "10.1136/gutjnl-2021-326874",

language = "English",

volume = "71",

pages = "2123--34",

journal = "Gut",

issn = "0017-5749",

publisher = "BMJ Publishing Group",

number = "10",

}

TY - JOUR

T1 - Current therapies and new developments in NASH

AU - Dufour, Jean Francois

AU - Anstee, Quentin M.

AU - Bugianesi, Elisabetta

AU - Harrison, Stephen

AU - Loomba, Rohit

AU - Paradis, Valerie

AU - Tilg, Herbert

AU - Wong, Vincent Wai Sun

AU - Zelber-Sagi, Shira

PY - 2022/6/16

Y1 - 2022/6/16

N2 - Non-alcoholic steatohepatitis is becoming the most importance etiology for advanced liver disease. The field made important progresses in the last years. The complexity of the pathophysiology of NASH is better understood. Multiple non-invasive criculating and imaging biomarkers have been tested. The importance of lifestyles has been reconised and several drugs are tested in clinical trials. This review adresses the challenges that face health care professionals in the management of NASH patients.

AB - Non-alcoholic steatohepatitis is becoming the most importance etiology for advanced liver disease. The field made important progresses in the last years. The complexity of the pathophysiology of NASH is better understood. Multiple non-invasive criculating and imaging biomarkers have been tested. The importance of lifestyles has been reconised and several drugs are tested in clinical trials. This review adresses the challenges that face health care professionals in the management of NASH patients.

UR - http://www.scopus.com/inward/record.url?scp=85132796389&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2021-326874

DO - 10.1136/gutjnl-2021-326874

M3 - Review article

C2 - 35710299

AN - SCOPUS:85132796389

SN - 0017-5749

VL - 71

SP - 2123

EP - 2134

JO - Gut

JF - Gut

IS - 10

M1 - 326874

ER -

Current therapies and new developments in NASH

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this